Michael Hudecek

Michael Hudecek

UNVERIFIED PROFILE

Are you Michael Hudecek?   Register this Author

Register author
Michael Hudecek

Michael Hudecek

Publications by authors named "Michael Hudecek"

Are you Michael Hudecek?   Register this Author

36Publications

1053Reads

49Profile Views

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells.

Sci Transl Med 2019 Jul;11(499)

Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, 97080 Würzburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aau5907DOI Listing
July 2019

Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T.

Nat Commun 2019 Jul 17;10(1):3137. Epub 2019 Jul 17.

Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Oberdürrbacherstrasse 6, 97080, Würzburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-10948-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637169PMC
July 2019

Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system.

Curr Opin Genet Dev 2018 10 12;52:100-108. Epub 2018 Oct 12.

Division of Medical Biotechnology, Paul Ehrlich Institute, Langen, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gde.2018.06.003DOI Listing
October 2018

CAR T cells targeting αβ integrin are effective against advanced cancer in preclinical models.

Adv Cell Gene Ther 2018 Sep 10;1(2). Epub 2018 Jul 10.

Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/acg2.11
Publisher Site
http://dx.doi.org/10.1002/acg2.11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226260PMC
September 2018

CARs and other T cell therapies for MM: The clinical experience.

Best Pract Res Clin Haematol 2018 06 27;31(2):147-157. Epub 2018 Mar 27.

Myeloma Service, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10065, New York, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2018.03.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602094PMC
June 2018

Current developments in immunotherapy in the treatment of multiple myeloma.

Cancer 2018 05 6;124(10):2075-2085. Epub 2018 Feb 6.

Department of Hematology, Oncology, and Stem Cell Transplantation, Department of Medicine I, University Medical Center Freiburg, Freiburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31243DOI Listing
May 2018

Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia.

Curr Res Transl Med 2018 05 11;66(2):37-38. Epub 2018 Apr 11.

Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.retram.2018.03.006DOI Listing
May 2018

SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7 normal lymphocytes.

Blood 2017 12 31;130(26):2838-2847. Epub 2017 Oct 31.

Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2017-04
Publisher Site
http://dx.doi.org/10.1182/blood-2017-04-778423DOI Listing
December 2017

Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side.

Crit Rev Biochem Mol Biol 2017 08 12;52(4):355-380. Epub 2017 Apr 12.

d Division of Medical Biotechnology , Paul Ehrlich Institute , Langen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10409238.2017.1304354DOI Listing
August 2017

Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.

Blood 2017 06 5;129(25):3386-3388. Epub 2017 May 5.

Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-03-770776DOI Listing
June 2017

Myeloma CARs are rolling into the clinical arena.

Blood 2016 09;128(13):1667-8

UNIVERSITÄTSKLINIKUM WÜRZBURG.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-08-729467DOI Listing
September 2016

The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.

Cancer Immunol Res 2015 Feb 11;3(2):125-35. Epub 2014 Sep 11.

Fred Hutchinson Cancer Research Center, Clinical Research Division, Program in Immunology, Seattle, Washington. Department of Medicine, University of Washington, Seattle, Washington. Technical University of Munich, Institute for Advanced Study, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692801PMC
February 2015

Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

Cancer Immunol Res 2015 Feb 29;3(2):206-16. Epub 2014 Oct 29.

Fred Hutchinson Cancer Research Center, Seattle, Washington. Department of Medicine, University of Washington, Seattle, Washington. Institute for Advanced Study, Technical University of Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0163DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324006PMC
February 2015

Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.

Clin Cancer Res 2013 Jun 25;19(12):3153-64. Epub 2013 Apr 25.

Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0330DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804130PMC
June 2013

Engineered T cells for anti-cancer therapy.

Curr Opin Immunol 2012 Oct 18;24(5):633-9. Epub 2012 Jul 18.

Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coi.2012.06.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3622551PMC
October 2012

Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.

Cancer Res 2009 Dec 10;69(23):8886-93. Epub 2009 Nov 10.

Department of Cancer Immunotherapeutics, Division of Neurosurgery, City of Hope National Medical Center, Duarte, California 91010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-09-2687DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2789196PMC
December 2009

Adoptive T-cell therapy for B-cell malignancies.

Expert Rev Hematol 2009 Oct;2(5):517-32

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.09.47DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118544PMC
October 2009